Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Active, not recruiting	Phase 2	2026-09-09		NCT06578559

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Gruppo Oncologico del Nord-Ovest	18
Merck Sharp & Dohme LLC	650
Pierre Fabre Laboratories	5

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
A.O.U. Citta Della Salute E Della Scienza Di Torino Presidio Molinette	Turin	Italy	1
AUSL Romagna	Ravenna	Italy	1
Azienda Ospedaliera Universitaria degli Studi di Campania L. Vanvitelli	Naples	Italy	1
Azienda Ospedaliero-Universitaria Pisana	Pisa	Italy	2
Azienda Sanitaria Universitaria Friuli Centrale	Udine	Italy	3
Fondazione Casa Sollievo Della Sofferenza - Irccs	San Giovanni Rotondo	Italy	1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Roma	Italy	14
IRCCS Istituto Nazionale dei Tumori di Milano	Milan	Italy	1
Istituto Oncologico Veneto Irccs	Padova	Italy	4
Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst	Meldola	Italy	2
L'Azienda Ospedaliero Universitaria di Cagliari	Monserrato	Italy	1
Nuovo Ospedale di Prato S. STEFANO	Prato	Italy	2
Pia Fondazione di Culto e di Religione Cardinale G. Panico	Tricase	Italy	1